TY - JOUR
T1 - Detection of high-risk HPV 16 genotypes in cervical cancers using isothermal DNA amplification with electrochemical genosensor
AU - Nakowong, Panisara
AU - Chatchawal, Patutong
AU - Chaibun, Thanyarat
AU - Boonapatcharoen, Nimaradee
AU - Promptmas, Chamras
AU - Buajeeb, Waranun
AU - Lee, Su Yin
AU - Jearanaikoon, Patcharee
AU - Lertanantawong, Benchaporn
N1 - Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2024/3/1
Y1 - 2024/3/1
N2 - Cervical cancer emerges as the third most prevalent types of malignancy among women on a global scale. Cervical cancer is significantly associated with the persistent infection of human papillomavirus (HPV) type 16. The process of diagnosing is crucial in order to prevent the progression of a condition into a malignant state. The early detection of cervical cancer through initial stage screening is of the utmost significance in both the prevention and effective management of this disease. The present detection methodology is dependent on quantitative polymerase chain reaction (qPCR), which necessitates the use of a costly heat cycler instrument. In this study, we report the development of an electrochemical DNA biosensor integrated with an isothermal recombinase polymerase amplification (RPA) reaction for the detection and identification of the high-risk HPV-16 genotype. The electrochemical biosensor exhibited a high degree of specificity and sensitivity, as evidenced by its limit of detection (LOD) of 0.23 copies/μL of HPV-16 DNA. The validity of this electrochemical platform was confirmed through the analysis of 40 cervical tissues samples, and the findings were consistent with those obtained through polymerase chain reaction (PCR) testing. Our straightforward electrochemical detection technology and quick turnaround time at 75 min make the assay suitable for point-of-care testing in low-resource settings.
AB - Cervical cancer emerges as the third most prevalent types of malignancy among women on a global scale. Cervical cancer is significantly associated with the persistent infection of human papillomavirus (HPV) type 16. The process of diagnosing is crucial in order to prevent the progression of a condition into a malignant state. The early detection of cervical cancer through initial stage screening is of the utmost significance in both the prevention and effective management of this disease. The present detection methodology is dependent on quantitative polymerase chain reaction (qPCR), which necessitates the use of a costly heat cycler instrument. In this study, we report the development of an electrochemical DNA biosensor integrated with an isothermal recombinase polymerase amplification (RPA) reaction for the detection and identification of the high-risk HPV-16 genotype. The electrochemical biosensor exhibited a high degree of specificity and sensitivity, as evidenced by its limit of detection (LOD) of 0.23 copies/μL of HPV-16 DNA. The validity of this electrochemical platform was confirmed through the analysis of 40 cervical tissues samples, and the findings were consistent with those obtained through polymerase chain reaction (PCR) testing. Our straightforward electrochemical detection technology and quick turnaround time at 75 min make the assay suitable for point-of-care testing in low-resource settings.
KW - Electrochemical DNA biosensor
KW - Human papilloma virus 16 screening
KW - Methylene blue intercalation
KW - Recombinase polymerase amplification
UR - http://www.scopus.com/inward/record.url?scp=85178169789&partnerID=8YFLogxK
U2 - 10.1016/j.talanta.2023.125495
DO - 10.1016/j.talanta.2023.125495
M3 - Article
C2 - 38043336
AN - SCOPUS:85178169789
SN - 0039-9140
VL - 269
JO - Talanta
JF - Talanta
M1 - 125495
ER -